Ventricular arrhythmias in patients with functional mitral regurgitation and implantable cardiac devices: implications of mitral valve repair with Mitraclip®

• DOI: 10.21037/atm.2020.02.45
• Publication Date: 2020-08-14T11:33:37Z
• Authors: Tomás Benito-Gonz...; Xavier Freixa; Cosmo Godino; Maurizio Taramasso; Rodrigo Estévez-L...; Daniel Hernandez-...; Ana Serrador; Luis Nombela-Franco; David Grande-Prada; Ignacio Cruz-Gonz...; Rodolfo San Antonio; Michele Galasso; Mara Gavazzoni; Carmen Garrote; Antonio Portolés-...; Pablo Avanzas; Felipe Fernández-...; Isaac Pascual
• Keywords: MitraClip; Functional mitral regurgitation

Background: Limited information has been reported regarding the impact of percutaneous mitral valve repair (PMVR) on ventricular arrhythmic (VA) burden. The aim this study was to address incidence VA and appropriate antitachycardia implantable cardiac defibrillator (ICD) therapies before after PMVR. Methods: We retrospectively analyzed all consecutive patients with heart failure reduce left ejection fraction (LVEF), functional regurgitation (FMR) grade 3+ or 4+ an active ICD resynchronizer who underwent PMVR in any eleven recruiting centers. Only complete available device monitoring from one-year one year were included. Baseline clinical echocardiographic characteristics collected at 12-months follow-up. Results: Ninety-three (68.2±10.9 years old, male 88.2%) enrolled. successfully performed success discharge 91.4%. At 12-month follow-up, we observed a significant reduction severity, NT-proBNP prevalence severe pulmonary hypertension kidney disease. Patients also referred improvement NYHA class showed non-significant trend reserve remodeling. After decrease non-sustained tachycardia (VT) (5.0±17.8 vs. 2.7±13.5, P=0.002), sustained VT fibrillation (0.9±2.5 0.5±2.9, P=0.012) (2.5±12.0 0.9±5.0, P=0.033) observed. Conclusions: related burden our cohort.